Education
About Us
Working with TipRanks
Follow Us
Baxter International (BAX)
NYSE:BAX
BAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.34 - $43.99
Previous CloseN/A
Volume899.70K
Average Volume (3M)5.24M
Market Cap
$16.98B
Enterprise Value$31.28B
Total Cash (Recent Filing)$1.76B
Total Debt (Recent Filing)$13.45B
Price to Earnings (P/E)136.1
Beta0.55
Next Earnings
Apr 24, 2025EPS Estimate
0.48Last Dividend Ex-Date
Feb 28, 2025Dividend Yield2.77%
Share Statistics
EPS (TTM)-1.27
Shares Outstanding511,625,000
10 Day Avg. Volume4,939,102
30 Day Avg. Volume5,237,111
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.60
Price to Cash Flow (P/CF)8.70
P/FCF Ratio4.60
Enterprise Value/Market Cap1.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.39
Enterprise Value/Ebitda32.86
Forecast
1Y Price Target
$38.10Price Target Upside13.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Baxter International News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ4 revenue and EPS of $2.75B and $0.58 beat Street targets of $2.67B and $0.52.
Market Share GrowthThe growth of infusion pumps remains strong, with BAX gaining approximately 2% market share and anticipates similar growth driven by increased demand for Novum.
Operational StabilityThe North Carolina facility is now producing at pre-hurricane levels, with manufacturing lines reaching full production, indicating recovery and operational stability.
Bears Say
Market ConfidenceBAX is likely to take a few quarters to regain confidence after a bumpy few years.
Sales DeclineHealthcare Systems & Technologies (HST) sales of $784M declined 1% on a reported and CC basis.
---
Ownership Overview
0.37% Insiders
33.50% Mutual Funds
32.27% Other Institutional Investors
9.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was $28.34 and its highest was $43.99 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $16.98B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Feb 20, 2025. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.528 by $0.052.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International pays a Quarterly dividend of $0.17 which represents an annual dividend yield of 2.77%. See more information on Baxter International dividends here
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.48.
How many shares outstanding does Baxter International have?
Baxter International has 511,625,000 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $0.58 in its last earnings report, beating expectations of $0.528. Following the earnings report the stock price went up 8.51%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in BAX
---
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.10 (13.39% Upside)
$38.10 (13.39% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 81%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.88%
12-Months-Change
Fundamentals
Return on Equity
-9.24%
Trailing 12-Months
Asset Growth
-8.82%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
---
BAX Company Deck
---
BAX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Baxter showed strong recovery and operational performance in Q4 2024, beating guidance and setting a positive tone for 2025. Despite challenges from Hurricane Helene and declines in Frontline Care, the company's strategic initiatives and product launches are expected to drive growth. The sentiment is balanced, with notable achievements in product launches and recovery efforts, but offset by the impact of external challenges and operational pressures.Read More>---
BAX Net sales Breakdown
55.00% U.S.
32.31% ROW
12.69% Emerging markets
---
BAX Stock 12 Month Forecast
Average Price Target
$38.10
▲(13.39% Upside)
Technical Analysis
Best Analysts Covering BAX
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
-0.35%
reiterated a buy rating last month
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.35% per trade.
---